Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.

Zofia Piotrowska, Catherine A. Shu, Elaine Shum et al.|Journal of Clinical Oncology|2023

Cited by 9